跳至主要内容
临床试验/ACTRN12622001336774
ACTRN12622001336774尚未招募未知

Changes in meibomian gland structure and function in adults suffering from dry eye disease following Intense Pulsed Light Therapy

niversity of New South Wales0 个研究点目标入组 34 人开始时间: 2022年10月18日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
34

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1.Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent
  • 2.Aged 18 years or over
  • 3.Minimum of 6 months since the onset of self-reported dry eye
  • 4.Have dry eye symptoms: Ocular Surface Disease Index score (OSDI) of >12 and Contact lens dry eye questionnaire (CLDEQ-8 greater than or equal to 12) (for contact lens users only) and evidence of MG obstruction i.e. meibomian gland secretion score greater Ethan or equal to 12
  • 5.May or may not use soft contact lenses
  • 6.All prescription medications have been used consistently for at least 3 months prior to the study, and no planned changes for the duration of the trial
  • 7.Willing to comply with the study visit schedule and adhere to instructions as directed by the Investigator

排除标准

  • 1. Any active anterior segment disease
  • 2.Any eyelid abnormality including lid lacerations
  • 3.Patients who are currently using topical ocular medication or have used topical ocular medication within 12 weeks of the first visit
  • 4.Any systemic disease that may affect ocular health e.g. Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, and systemic lupus erythematosus;
  • 5.Gas permeable contact lens wearer (including ortho-k) within 6 months of the first visit
  • 6.Anyone who has received clinical skin treatments within the prior 2 months, or implants beneath the treatment area including tattoos, semi-permanent makeup, or pigmented lesions
  • 7.Dark pigmented skin tone according to Fitzpatrick scale V/VI (very dark or black skin), which is prone to skin damage, such as discoloration or scarring after IPL treatment (according to the manufacturer’s guidelines)
  • 8.Skin cancer, the user of photosensitive drugs /foods
  • 9.Anyone who has previously received IPL therapy for dry eye treatment
  • 10.Pregnancy or breastfeeding.

研究者

相似试验